BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) does about 6.90M shares in volume on a normal day but saw 15242575 shares change hands in Monday trading. The company now has a market cap of 723.47M USD and an enterprise value of about $588.22M. Its current market price is $4.15, marking an increase of 4.53% compared to the previous close of $3.97. The 52 week high reached by this stock is $6.29 whilst the lowest price level in 52 weeks is $1.38. The script in recent trading has seen the stock touch a high of $4.49 and a low of $4.06.
BioCryst Pharmaceuticals Inc. (BCRX) has a 20-day trading average at $4.17 and the current price is -33.98% off the 52-week high compared with 200.72% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.53 and its 200-day simple moving average is $3.52. If we look at the stock’s price movements over the week, volatility stands at 6.25%, which increases to 6.47% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.65 to suggest the stock is neutral.
FactSet Research has provided data showing that 9 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 6 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 17, 2020 when BTIG Research initiated the stock to “Neutral” and issued a price target of . Barclays upgraded the stock to “Overweight” from Equal Weight on May 05, 2020 at a price target of $7. BofA/Merrill upgraded its price target at $5-$4.
The current price level is -0.83%, -8.38%, and 18.21% away from its SMA20, SMA50, and SMA200 respectively, with the BCRX price moving above the 50-day SMA on August 31. BioCryst Pharmaceuticals Inc. (BCRX) stock is up 4.67% over the week and 1.97% over the past month. Its price is 20.29% year-to-date and 38.80% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.24 above consensus estimates by $0.01. The company’s next earnings report is expected on 11/10/2020, with forecasts estimating quarterly EPS at -$0.25 and -$0.93 for whole year. BCRX’s earnings per share are forecast to grow by 1.10% this year and 10.80% over next year. Expected sales for next quarter are $20.86 million, which analysts say will come at $30.65 million for the current fiscal year and next year at $56.3 million. In addition, estimates put the company’s current quarterly revenue at an average of $3.56 million.
Its 12-month price target is $8.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $4.50, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $13.00.
Outstanding shares total 161.57M with insiders holding 0.95% of the shares and institutional holders owning 90.20% of the company’s common stock. The company has a return on investment of -84.10% and return on equity of -603.60%. The beta has a value of 2.60. Price to book ratio is 8.83 and price to sales ratio is 14.70.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has reduced its position in BioCryst Pharmaceuticals Inc. (BCRX) to 13,538,612 shares, mirroring a recent drop by -0.99%. SPDR S&P Biotech ETF dumped -0.14 million shares of BioCryst Pharmaceuticals Inc. common stock bringing its total worth to about $55.1 million at the end of recent close, SEC documents show. SPDR S&P Biotech ETF isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 1576.0 shares to end up with 4,998,398 shares worth $20.34 million. iShares Russell 2000 ETF cut their holdings by -4.47% in the company over the course of the most recent quarter. It now holds a 1.82% position in BioCryst Pharmaceuticals Inc. thanks to 3.21 million shares amounting to $13.05 million.